Using a multi-infusion strategy to reduce infections in premature infants
Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections
This study tests if using special devices to give multiple medications can help reduce infections in premature infants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 455 (estimated) |
| Ages | N/A to 32 Weeks |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 3 sites (Bron, France and 2 other locations) |
| Trial ID | NCT06656104 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the impact of a multi-infusion strategy on the rate of central line-associated bloodstream infections (CLABSI) in premature infants. The approach involves using specialized infusion devices designed to minimize the risk of microbial contamination while administering multiple intravenous medications and nutrition. The study aims to assess whether this strategy can reduce the incidence of infections and the need for antibiotics in this vulnerable population. Infants who meet specific eligibility criteria will be monitored for infection rates during their hospitalization.
Who should consider this trial
Good fit: Ideal candidates for this study are premature infants born at or before 32 weeks of gestation and weighing 1600 grams or less, who require intravenous infusions.
Not a fit: Patients with lethal or complicated malformations or chromosomal anomalies may not benefit from this study.
Why it matters
Potential benefit: If successful, this strategy could significantly reduce the risk of infections in premature infants, leading to better health outcomes.
How similar studies have performed: While this approach is innovative, similar strategies in other settings have shown promise in reducing infection rates, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gestational age at birth ≤ 32 weeks * Birthweight ≤ 1600 g * Admitted in the first 3 days of life in the neonatal unit * Hospitalized in the neonatal unit for at least 1 day * Survived the first three days of life * Requires the use of infusion sets for the administration of multiple drugs or solutions, whether or not they have the device in place * Receipt of the non-opposition from parents or guardians Exclusion Criteria: * Opposition by parents or guardians * Lethal or complicated malformation * Chromosomal anomaly * Participation of the infant in any other research that may interfere with the results of this study, in the judgment of the investigator
Where this trial is running
Bron, France and 2 other locations
- Service de néonatologie Hôpital Femme Mère Enfant — Bron, France, France (Recruiting)
- Service Pédiatrie néonatale et réanimations CHU Montpellier — Montpellier, France, France (Not_yet_recruiting)
- Service de néonatologie CHU de Strasbourg — Strasbourg, France, France (Active_not_recruiting)
Study contacts
- Study coordinator: Jean-Charles PICAUD, MD, PhD
- Email: jean-charles.picaud@chu-lyon.fr
- Phone: 04 72 00 15 50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.